Working inthe Centauri lab

Revolutionising immunotherapy for the most vulnerable patients through our novel Alphamer® technology.

Centauri Therapeutics is an immunotherapy company currently focused on infectious diseases and oncology. Centauri’s approach to treating infectious diseases rests upon proprietary Alphamer® technology. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases.

Latest News and Articles

Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate

February 24, 2026

See attached press release

Read More

Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

July 29, 2025

See attached press release

Read More

Centauri Therapeutics appoints Dr. Debra Barker as Chief Medical Officer

July 8, 2025

See attached press release

Read More